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ABSTRACT
Aims To report progress among Parties to theWorld Health Organization (WHO) Framework Convention on Tobacco
Control (FCTC) in developing national tobacco treatment guidelines in accordance with FCTC Article 14 guideline
recommendations. Design Cross-sectional study. Setting Electronic survey from December 2011 to August 2012;
participants were asked to complete either an online or attached Microsoft Word questionnaire. Participants One
hundred and sixty-three of the 173 Parties to the FCTC at the time of our survey. Measurements The 51-item
questionnaire contained 30 items specifically on guidelines. Questions covered the areas of guidelines writing process,
content, key recommendations and other characteristics. Findings One hundred and twenty-one countries (73%)
responded. Fifty-three countries (44%) had guidelines, ranging from 75% among high-income countries to 11%
among low-income countries. Nearly all guidelines recommended brief advice (93%), intensive specialist support
(93%) and medications (96%), while 66% recommended quitlines. Fifty-seven percent had a dissemination strategy,
76% stated funding source and 68% had professional endorsement. Conclusion Fewer than half of the Parties to
the WHO FCTC have developed national tobacco treatment guidelines, but, where guidelines exist, they broadly
follow FCTC Article 14 guideline recommendations.
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treatment.
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INTRODUCTION
Article 14 of the World Health Organization (WHO)
Framework Convention on Tobacco Control (FCTC)
‘Demand reduction measures concerning tobacco
dependence and cessation’, requires Parties to develop
and disseminate comprehensive guidelines based on sci-
entific evidence, and to take effective measures to
promote cessation of tobacco use and adequate treat-
ment for tobacco dependence [1]. In November 2010, the
fourth conference of the Parties to the FCTC adopted
guidelines for the implementation of Article 14. These
guidelines amount to official policy on tobacco depend-
ence treatment for Parties to the Convention, and, inter
alia, outline the key characteristics of national guide-
lines, which should [1]:
1 Be comprehensive—include a broad range of interven-
tions, such as the identification of tobacco users and the
provision of brief advice, behavioural support provided
by telephone quitlines and face-to-face, access to free
or affordable medications, and cover all settings and
all providers within and outside the health-care sector
2 Be evidence based
3 Include a dissemination and implementation plan
4 Emphasise the importance of all service providers
setting a good example by not using tobacco and that
they should be helped to stop
5 Be developed through active collaboration between
government and other relevant stakeholders, includ-
ing health professional organisations, and be endorsed
widely at national level, including by health profes-
sional organisations
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6 Be protected from conflicts of interest during their
development
7 Be reviewed periodically and updated as necessary.
In this article we report the results of a survey whose
objective was to review the state of tobacco dependence
treatment systems and treatment guidelines among
Parties to the FCTC in order to gauge progress in imple-
menting Article 14 and the Article 14 guidelines. The
survey builds on a previous survey whose results were
published in 2009 [2,3]. We report here the guidelines
results; the treatment systems results are reported in a
separate article (submitted for publication).
METHODS
Sample
The 2009 study [2] used a convenience sample of 31
countries. For this studywe sought to survey all Parties to
the FCTC. We developed a contact list in a stepwise way,
startingwith contacts from the last survey and other con-
tacts in the treatment field known to us, including
through the FCTC Article 14 working group. We then
used contacts from the Framework Convention Alliance
(FCA), a civil society alliance that promotes FCTC imple-
mentation, and Global Bridges, a network of health-care
professionals that advocate effective tobacco control poli-
cies and run training courses. Finally, we found some
contacts with help from WHO regional offices. Our con-
tacts were a mixture of treatment specialists, FCA
members and government officials.
At the time of our survey therewere 174 Parties to the
FCTC. This number included the European Union (EU), as
well as its 27 member states, so we excluded the EU
(which obviously cannot have national guidelines),
leaving 173 Parties. From the 173 Parties we were
unable to find contacts in 10 Parties, thus 163 Parties
were surveyed. The UK, which is a Party, consists of four
countries—England, Northern Ireland, Scotland and
Wales—each with separate health-care systems and
treatment guidelines, so we surveyed all four individually.
Our final sample therefore consisted of 163 FCTC Parties
or 166 countries.
We emailed 166 people, starting in December 2011,
inviting them to participate in our survey by clicking on a
link to the online survey contained in the email, or by
completing an attached Microsoft Word questionnaire
(offered in English, French and Spanish). We followed up
non-responders with reminder emails in January, Febru-
ary, April and May 2012.
Where we needed clarification of answers we corre-
sponded with contacts, until mid-August, when the
survey was closed.
Countries were categorised by WHO region, and
World Bank income level [4,5].
Questionnaire
The questionnaire was based on the 2009 questionnaire
[2], updated in the light of the FCTC Article 14 guide-
lines, then discussed iteratively and agreed by the survey
team.The questionnaire contained 51 items, 21 on treat-
ment and 30 specifically on guidelines. The guidelines
questions are shown in Tables 1 and 2.
Descriptive analyses were used to show the distribu-
tion of our respondents by WHO region and national
income category. All analyses were carried out using IBM
SPSS statistical software version 19.
RESULTS
Survey response rates
We received responses from 121 (73%) of the 166 coun-
tries surveyed.
Response rates ranged from 65% of countries sur-
veyed in the Western Pacific region to 83% in Europe
and Southeast Asia, and from 67% of surveyed lower-
middle-income countries to 78% of surveyed high-
income countries (Fig. 1). Our United Arab Emirates
contact completed the survey only for Abu Dhabi.
Countries with guidelines by region and income level
Fifty-three of the 121 countries (44%) reported
having treatment guidelines. Twenty-seven (75%) of the
high-income countries, 15 (42%) upper-middle-income
countries, 9 (30%) lower-middle-income countries and
2 (11%) low-income countries had guidelines.
Table 1 Guideline content.
Question % Yes (n)
Are the guidelines for the whole healthcare
system and all health professionals and other
relevant groups?
72 (38)
Do the guidelines recommend brief advice? 93 (49)
Do the guidelines recommend quitlines? 66 (35)
Do the guidelines recommend intensive specialist
support?
93 (49)
Do the guidelines recommend medications? 96 (51)
Do the guidelines include evidence on cost
effectiveness?
45 (24)
Do the guidelines reference or refer to the
Cochrane Library?
68 (36)
Do the guidelines reference or refer to the
guidelines of other countries?
68 (36)
Are the guidelines based on another country’s
guidelines or other guidelines?
55 (29)
Do the guidelines stress the importance of service
providers setting an example by not using
tobacco?
57 (30)
Note: all questions answered yes/no; the base was the 53 countries with
guidelines; missing data ranged from 2 to 8%.
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Eight (40%) countries from the Americas, 27 (69%)
fromtheEuropean region,5 (42%) fromtheEasternMedi-
terranean, 3 (60%) from Southeast Asia and 10 (59%)
fromtheWesternPacific regionhadguidelines.None from
the African region had treatment guidelines (Fig. 2).
Guideline content
The base for the figures given in the following sections is
the 53 countries that have guidelines; key guideline
content is shown in Table 1.
Thirty-eight guidelines (72%) were for the whole
health-care system and all health professionals. Those
not for the whole health-care system were specifically
for primary care, nursing, pharmacy, dentists, pregnant
tobacco users, doctors outside primary care, teachers,
churches, psychiatric patients or psychiatrists.
Key guideline recommendations
Almost all guidelines recommended brief advice (93%),
intensive specialist support (93%) and medications
(96%), and 66% recommended quitlines. Of the 51
guidelines that recommendedmedications (only 1 did not
recommend medications), all recommended nicotine
replacement therapy, 46 (90%) recommended bupro-
pion, 38 (75%) recommended varenicline, 6 (12%)
recommended cytisine and 4 (8%) recommended
nortriptyline.
Other guideline content
Forty-five percent of guidelines included evidence on
cost-effectiveness, 68% referenced or referred to the
Cochrane library, 68% referenced or referred to guide-
lines of other countries, and 55% were based on those of
at least one other country. The USA, UK andNew Zealand
were the three countries whose guidelines were most
Table 2 Guidelines writing process.
Question % Yes (n)
Is there a strategy to disseminate the guidelines? 57 (30)
Did national professional associations participate
in drafting or reviewing them?
70 (37)
Are the guidelines formally endorsed by national
professional associations?
68 (36)
Are they formally endorsed or supported by your
national government?
70 (37)
Do they clearly describe the writing and review
process?
66 (35)
Were they peer-reviewed? 72 (38)
Do they clearly state who funded the guidelines? 76 (40)
Did they receive financial support from
government or other public health
organisations?
77 (41)
Did they receive financial support from the
pharmaceutical industry?
15 (8)
Do they include conflict-of-interest statements for
all authors?
40 (21)
Do the names and/or logos of any
pharmaceutical companies appear in the
guidelines?
11 (6)
Note: all questions answered yes/no; the base was the 53 countries with
guidelines; missing data ranged from 2 to 8%.
Figure 1 Survey response rates by region and income level
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frequently referenced or referred to, or upon which
national guidelines were based. Fifty-seven percent
stressed the importance of service providers setting an
example by not using tobacco.
Guideline writing process
Fifty-seven percent of guidelines had a dissemination
strategy (Table 2). National professional associations
were involved in drafting 70%, while 68% were endorsed
by national professional associations. Of the guidelines
that were formally endorsed by national professional
associations, 78% of themwere endorsed by 1–9 associa-
tions, while 22% were endorsed by 10 or more. Seventy
percent of guidelines were formally endorsed or sup-
ported by the national government. Sixty-six percent of
guidelines clearly described the writing and review
process, and 72% were peer reviewed.
Seventy-six percent of guidelines stated who funded
them; 77% received financial support from government
or other public health organizations; 15% received finan-
cial support from the pharmaceutical industry; and 11%
contained the names and/or logos of pharmaceutical
companies, while 40% included conflict of interest state-
ments for all authors.
Twenty-three guidelines (43%) were published in or
after 2010. Several guidelines were published in more
than one place. Forty-three (81%) were published as a
report or a book, 29 (55%) were published online, 12
(23%) were published in peer reviewed scientific journals
and 1 (2%) was published as a supplement to medical
journals.
DISCUSSION
In this global tobacco treatment survey, just under half
of the countries surveyed had national treatment guide-
lines, and our results suggest that most were broadly in
line with the evidence base, recommending brief advice,
intensive specialist support, medications and quitlines,
and most were peer reviewed. Most were developed in a
collaborative way, involving national professional associa-
tions in drafting and being formally supported by govern-
ment.Mostclearlydescribedthewritingandreviewprocess;
however, fewer than half included conflict of interest state-
ments for all authors, and some received financial support
from the pharmaceutical industry and even included the
names and logos of pharmaceutical companies.
The main limitation of our study is that there was no
wayof verifying theaccuracyof surveyresponses.However,
we selected our survey contacts as carefully as we could
by using tobacco treatment specialists known to us, and
other tobacco control specialists recommended by profes-
sional colleagues and highly respected organisations. The
process of identifying guidelines was limited in that it was
not always possible to identify a contact in all Parties to the
FCTC and, in cases where we did identify contacts, to get
Figure 2 Countries that have treatment guidelines by region and income level
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responses from them despite sending reminder emails.
Nevertheless, we did get in touch with contacts in all
but 10 Parties to the FCTC, and, based on the knowledge
we have of guidelines from our previous survey [2] and
the guidelines available on http://www.treatobacco.net,
we believe that our sample is highly likely to have
captured virtually all, if not all, existing guidelines.
To our knowledge this is the largest ever detailed
global survey of tobacco dependence treatment, with a
response rate of 73% (121 countries). Results reported
here are for 68% of FCTC Parties, and show good global
representation, includingwell over half of allWorld Bank
income categories andWHO regions. The lowest response
rate by region was in the Western Pacific region (65%),
and the highest in Europe and Southeast Asia (83%).
Fifty-three countries (44%) reportedhaving guidelines
and38 (31%) reported that these guidelineswere compre-
hensive,meaning for thewholehealth-care systemandall
health-care professionals. There was a linear relationship
between income level and having guidelines, with results
ranging from 75% of high-income countries to 11% of
low-incomecountries (Fig. 2).Guidelinedevelopment can
be time consuming and expensive, and this may suggest
that development of treatment guidelines is not a priority
formiddle- and low-income countries. None of the Parties
surveyed from the African region had guidelines; more
than half the countries in the region are low-income and
almost a quarter are lower-middle-income [5]. Interest-
ingly, Africa has the lowest annual per capita cigarette
consumption of all theWHO regions [6] and perhaps this,
inter alia, makes treatment guidelines a low priority for
Parties in the region. Lack of money and lack of expertise
were cited as reasons for not having treatment guidelines
in a previous survey [2].
The apparently low priority given to development of
treatment guidelines may also reflect a rational response
not just to their potential cost but also to the broad
content of the FCTC itself [7] and theMPOWERmeasures
[8–10]. These emphasise the implementation of policies,
such as smoke-free legislation, higher taxation, advertis-
ing bans, large graphic health warnings and education
on the dangers of tobacco, in order to promote cessation
at population level. Logically, until those measures are in
place and generating demand for cessation support, it
would not make sense to devote substantial resources to
developing such support. Furthermore, at the start of our
survey it had only been 1 year since the FCTC Article 14
guidelineswere adopted, which is very little time inwhich
to develop guidelines in accordance with FCTC recom-
mendations. It is therefore likely that some Parties are
currently developing guidelines. Given that 57% of
guidelines in our survey were published before 2010,
arguably even Parties with guidelines may consider
updating them at some point in the near future.
We already commented that most guidelines recom-
mended brief advice, intensive specialist support, medica-
tions and quitlines. The Cochrane library was referenced
or referred to by the majority of guidelines, suggesting
that the FCTC recommendation that guidelines should be
‘based on scientific evidence’ is being taken seriously.
Over half of the guidelines were based on those of other
countries, mostly the US and UK guidelines, possibly a
very practical cost-saving approach.
Akeyfinding, however,was that only57%of countries
said they had a strategy to disseminate their guidelines.
Given that, logically, national guidelines will form the
basis for treatment services, the lack of a dissemination
plan is of concern, and the FCTC Article 14 guidelines
clearly state that national guidelines should include a
dissemination plan. However, in some countries the
existence of official national guidelines is a powerful state-
ment of the importance of the issue, so even without a
dissemination strategy, guidelines can be very important.
Rates of tobacco use by health professionals are very
high in some countries [11], which is why the FCTC
Article 14 guidelines recommend that guidelines stress
the importance of health-care providers not using
tobacco and of helping them stop. In spite of this, only
57% of guidelines stress this.
The high proportions of guidelines that involved
national professional associations in their drafting (70%),
which were formally supported by government (70%)
and by public health organisations (68%), and which
received financial support from government or other
public health organisations (77%), suggests that the
majority of the guidelines were produced as a result of
genuine collaboration between relevant stakeholders, a
recommendation of the FCTC Article 14 guidelines. We
believe such collaboration is important for at least two
reasons: no country has unlimited resources so all
resources available should be used; and the failure of
genuine collaboration can result in real confusion, as in
one countrywe surveyed that has fractured national con-
sensus on treatment and three ‘competing’ guidelines.
Furthermore, it is likely that this collaboration resulted
in the high levels of endorsement from national health
professional organisations and governments.
Fifteen percent of guidelines in our survey received
financial support from the pharmaceutical industry, 11%
carried pharmaceutical company names and/or logos (in
one case a logo on the title page), and fewer than half
included conflict-of-interest statements for all authors.
The FCTC Article 14 guidelines do not actually prohibit
pharmaceutical company support, but do state that the
development process must be protected from vested inter-
ests. Arguably it is at least unwise to develop guidelines
with such industry support, but, in our opinion, it is
entirely unacceptable to promote company names and
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logos in guidelines. If pharmaceutical company funding
is considered necessary, then there must be very clear
rules to guarantee the independence and integrity of the
guidelines. However guideline development need not be
expensive, as tools are being developed to assist countries,
whichwould greatly reduce costs andwhichwill be avail-
able in 2013. We believe this route to be far preferable to
pharmaceutical company funding, which will, inevitably,
in many peoples’ views undermine guidelines. Finally, we
believe that full declaration of all interests is essential.
Overall, our findings suggest that the development of
guidelines is not yet a priority for many Parties to the
FCTC, but that most existing guidelines followed Article
14 guideline recommendations quite closely. The aim of
treatment guidelines is to assist health care practitioners
and patients in making decisions regarding tobacco
dependence and cessation [1], and yet the majority of
FCTC Parties do not have guidelines. The cost of produc-
ing guidelines appears to be a significant barrier; there-
fore, initiatives to provide technical and/or financial
support to resource limited countries are likely to expedite
guidelines development in these Parties.
The finding that themajority of existing guidelines are
based on the guidelines of other countries shows that
guideline production need not necessarily start from
scratch and may provide a way to help resource limited
countries. The development and dissemination of a
guidelines ‘template’, so to speak, which FCTC Parties
could subsequently tailor to suit their respective national
situations may translate into significant time and cost
savings for Parties and spur progress with guidelines
development. Although the focus of this report is the
FCTC Article 14 significant gains can only be made if
other complementary FCTC Articles are implemented
concurrently by Parties.
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